Cargando…

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm

SIMPLE SUMMARY: Mutation and protein-level profiling has expanded our understanding of the pathogenesis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and offered insights into potential therapeutic vulnerabilities. However, the prognostic impact of gene mutations in this disease remains co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, C. Cameron, Pemmaraju, Naveen, You, M. James, Li, Shaoying, Xu, Jie, Wang, Wei, Tang, Zhenya, Alswailmi, Omar, Bhalla, Kapil N., Qazilbash, Muzaffar H., Konopleva, Marina, Khoury, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656770/
https://www.ncbi.nlm.nih.gov/pubmed/34884997
http://dx.doi.org/10.3390/cancers13235888
Descripción
Sumario:SIMPLE SUMMARY: Mutation and protein-level profiling has expanded our understanding of the pathogenesis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and offered insights into potential therapeutic vulnerabilities. However, the prognostic impact of gene mutations in this disease remains controversial, and studies integrating the mutational landscape with cytogenetic and immunophenotypic characteristics in a real-world clinical context remain limited. We provide an overview of genotypic and phenotypic characteristics of a large, single-institution cohort of BPDCN patients. Besides gene mutations in DNA methylation and histone modification, BPDCN cells often harbor mutations affecting signal transduction, RNA splicing components, and transcription factors, particularly ETV6 and IKZF1. Older age, multiple mutations, and mutations in the DNA methylation pathway are poor prognostic factors. ABSTRACT: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive neoplasm derived from plasmacytoid dendritic cells. While advances in understanding the pathophysiology of the disease have been made, integrated systematic analyses of the spectrum of immunophenotypic and molecular alterations in real-world clinical cases remain limited. We performed mutation profiling of 50 BPDCN cases and assessed our findings in the context of disease immunophenotype, cytogenetics, and clinical characteristics. Patients included 42 men and 8 women, with a median age of 68 years (range, 14–84) at diagnosis. Forty-two (84%) patients had at least one mutation, and 23 (46%) patients had ≥3 mutations. The most common mutations involved TET2 and ASXL1, detected in 28 (56%) and 23 (46%) patients, respectively. Co-existing TET2 and ASXL1 mutations were present in 17 (34%) patients. Other recurrent mutations included ZRSR2 (16%), ETV6 (13%), DNMT3A (10%), NRAS (10%), IKZF1 (9%), SRSF2 (9%), IDH2 (8%), JAK2 (6%), KRAS (4%), NOTCH1 (4%), and TP53 (4%). We also identified mutations that have not been reported previously, including ETNK1, HNRNPK, HRAS, KDM6A, RAD21, SF3A1, and SH2B3. All patients received chemotherapy, and 20 patients additionally received stem cell transplantation. With a median follow-up of 10.5 months (range, 1–71), 21 patients achieved complete remission, 4 had persistent disease, and 24 died. Patients younger than 65 years had longer overall survival compared to those who were ≥65 years (p = 0.0022). Patients who had ≥3 mutations or mutations in the DNA methylation pathway genes had shorter overall survival (p = 0.0119 and p = 0.0126, respectively). Stem cell transplantation significantly prolonged overall survival regardless of mutation status. In conclusion, the majority of patients with BPDCN have somatic mutations involving epigenetic regulators and RNA splicing factors, in addition to ETV6 and IKZF1, which are also frequently mutated. Older age, multiple mutations, and mutations in the DNA methylation pathway are poor prognostic factors.